Abstract:Diabetic kidney disease (DKD) is the worldwide leader in end-stage kidney failure and has limited treatment options. Cellular senescence abundance and inflammation contribute to DKD pathogenesis. We previously demonstrated that activin A, an inflammatory mediator of pro-fibrotic kidney injury and cellular senescence, is increased in DKD and correlates with DKD injury and kidney function. We hypothesized that activin A contributes to DKD injury causing pro-fibrotic, pro-inflammatory, and cellular senescence effects in vitro, and that antagonism of activin A is achieved with follistatin. An in vitro model of DKD injury was applied with high-glucose (HG) and transforming growth factor-β (TGFβ) exposure for 24 hours in U-937-derived macrophages and renal epithelial (HK2) cells. Prior to exposure, U-937 cells were converted to M0 macrophages with phorbol myristate acetate (PMA). To examine the potential of reducing activin A release by DKD injured cells, follistatin, an activin A antagonist, was added to the media of cells at the time of injury for 24 hours. Additionally, an activin A neutralizing antibody was added to the collected supernatant of DKD injured cells. Activin A, senescence (p16), pro-fibrotic (collagen I), and pro-inflammatory (monocyte chemoattractant protein [MCP]-1, tumor necrosis factor [TNF]-alpha, interleukin [IL]-6) markers were measured through qPCR, ELISA (activin A), and immunofluorescence staining (activin A). DKD injury in renal epithelial cells increased protein expression of activin A, increased gene expression of activin A, p16, and collagen I, but did not significantly increase MCP-1 expression at 24 hour exposure (Figure 1). Furthermore, DKD injury led to increased activin A release in conditioned medium vs. control renal epithelial cells. Administration of follistatin reduced activin A release by renal epithelial cells. Application of neutralizing antibody reduced activin A levels in collected medium after cell injury. After DKD injury in U-937 derived macrophages, activin A gene expression was increased. Injured macrophages had increased gene expression of TNF-alpha and IL-6, demonstrating a pro-inflammatory phenotype. In conclusion, diabetic kidney injury increases activin A release, inflammation markers, and senescence markers in kidney cells and macrophages, therein contributing to downstream effects that further propagate disease. As shown, follistatin antagonism reduces activin A release by injured cells. Additional studies are needed to explore activin A as a promising therapeutic target and follistatin as a possible treatment in DKD. NIH 5TL1TR002380-07, AG076537, DK123492, DK109134. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Synergistic Effects of Activ in A and Fibroblast Growth Factor 2 in the M Odulation of Insulin Expression

Insulin Regulates the Expression of the Enhancer of Split- and Hairy-Related Protein-2 Gene Via Different Pathways in 3T3-L1 Adipocytes and L6 Myotubes

Effects of insulin growth factor I and bone morphogenetic protein-2 combined application on promoting proliferation and differentiation of MC 3T3-E1 and NIH 3T3 cells

[Effects of IGF-I and BMP-2 Combined Application on Promoting Proliferation, Differentiation and Calcification of MC 3T3-E1 and NIH 3T3 Cells].

Asiatic Acid Improves Insulin Secretion of Β Cells in Type 2 Diabetes Through TNF-α/Mfn2 Pathway.

Synergistic Proliferation Induced by Insulin and Glycated Serum Albumin in Rat Vascular Smooth Muscle Cells.

Differential Regulation of Mouse Pancreatic Islet Insulin Secretion and Smad Proteins by Activin Ligands.

Mitofusin2 Promotes Β Cell Maturation from Mouse Embryonic Stem Cells Via Sirt3/Idh2 Activation

Inhibition of MEF2A prevents hyperglycemia-induced extracellular matrix accumulation by blocking Akt and TGF-β1/Smad activation in cardiac fibroblasts

Tansforming growth factor-β regulates insulin gene expression in isolated rat islets

Insulin induces epidermal growth factor (EGF) receptor clustering and potentiates EGF‐stimulated DNA synthesis in Swiss 3T3 cells: A mechanism for costimulation in mitogenic synergy

Insulin Induces Proliferation and Cardiac Differentiation of P19CL6 Cells in a Dose‐dependent Manner

Activin A Contribution to Diabetic Kidney Disease Injury and Effects of Activin A Antagonism In-Vitro

A2a adenosine receptor agonist improves endoplasmic reticulum stress in MIN6 cell line through protein kinase A/ protein kinase B/ Cyclic adenosine monophosphate response element‐binding protein/ and Growth Arrest And DNA‐Damage‐Inducible 34/ eukaryotic Initiation Factor 2α pathways

Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143

FGF19 Promotes the Proliferation and Insulin Secretion from Human Pancreatic β Cells Via the IRS1/GLUT4 Pathway

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model

Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.

Sustained Remission of Type 2 Diabetes in Rodents by Centrally Administered Fibroblast Growth Factor 4

E2F1 transcription factor mediates a link between fat and islets to promote β cell proliferation in response to acute insulin resistance

Inhibition of myocyte-specific enhancer factor 2A improved diabetic cardiac fibrosis partially by regulating endothelial-to-mesenchymal transition